Citations
Sargeant, J., Henson, J., King, J., Yates, T., Khunti, K., & Davies, M. (2019). A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinology and Metabolism, 34, 247 - 262. https://doi.org/10.3803/EnM.2019.34.3.247.
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017). Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 10, 403 - 412. https://doi.org/10.2147/DMSO.S141235.
, , , et al. Nutritional considerations with antiobesity medications. Obesity (Silver Spring). 2024; 32(9): 1613-1631. doi:10.1002/oby.24067